Gary Goldenberg, MD, opened day 2 with an extensive review of the latest research on a broad range of dermatologic conditions, including acne vulgaris, psoriasis, atopic dermatitis (AD), alopecia areata, vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), seborrheic dermatitis, actinic keratosis (AK), chronic spontaneous urticaria (CSU), melanoma, onychomycosis, and cosmetic treatments. He began with acne vulgaris, highlighting innovative treatments such as clindamycin phosphate 1.2%, adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB gel), clascoterone, sarecycline, trifarotene cream, and 1726 nm laser. CAB gel, shown to outperform dual combinations and vehicle gel in Phase 2 and 3 trials, and clascoterone, which demonstrated improvement in acne lesions, pore size, and shine by week 12, were particularly noteworthy. Sarecycline, a new antimicrobial with better gut microbiome preservation, also stood out. Dr Goldenberg then transitioned to psoriasis, discussing biologic advancements such as risankizumab, guselkumab, and bimekizumab, as well as alternatives like the 308 nm excimer laser. He reviewed AD therapies, including roflumilast, dupilumab, and lebrikizumab, before covering alopecia areata treatments like ritlecitinib and baricitinib. For vitiligo, he presented promising data on ruxolitinib and upadacitinib, alongside preclinical studies of VY201. HS therapies featured novel agents such as MC2-32, while PN, seborrheic dermatitis, and AK saw advancements in dupilumab, roflumilast foam, and tirribanibulin ointment, respectively. He concluded with updates on CSU, melanoma diagnostics, and cosmetic innovations, showcasing the latest in cutting-edge dermatology research.